Insider · CIK 0001889716
Valerie Malyvanh Jansen
officerdirector
Files at OKUR (OnKure Therapeutics, Inc.), ELEV (Elevation Oncology, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 28, 2025 | OKUR OnKure Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +7,650 | $0.00 | $0 | 7,650 | May 30, 2025 |
| Feb 15, 2025 | ELEV Elevation Oncology, Inc. | MOption exercise Common Stock | +17,500 | - | - | 17,500 | Feb 19, 2025 |
| Feb 15, 2025 | ELEV Elevation Oncology, Inc. | FTax withholding Common Stock | -5,189 | $0.67 | $3,485 | 12,311 | Feb 19, 2025 |
| Feb 15, 2025 | ELEV Elevation Oncology, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +275,000 | $0.00 | $0 | 275,000 | Feb 19, 2025 |
| Feb 15, 2024 | ELEV Elevation Oncology, Inc. | MOption exercise Restricted Stock Unitderivative | -17,500 | $0.00 | $0 | 52,500 | Feb 19, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.